⌘K

Login Start Free

REGENERON PHARMACEUTICALS, INC.|4Feb 24, 4:07 PM ET

VAGELOS P ROY 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 24, 2023

Insider Transaction Report

Form 4

Period: 2023-02-22

REGENERON PHARMACEUTICALS, INC.REGN

Director

Transactions

Exercise/Conversion
Common Stock
2023-02-22$270.43/sh+42,500$11,493,275→ 366,583 total
Tax Payment
Common Stock
2023-02-22$750.16/sh−29,005$21,758,391→ 337,578 total
Gift
Common Stock
2023-01-04−291→ 125,752 total(indirect: by CLAT)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-02-22−42,500→ 85,000 total
Exercise: $270.43Exp: 2023-12-13→ Common Stock (42,500 underlying)

Holdings

Common Stock
(indirect: By 401(k))
1,963
Common Stock
(indirect: By Trust)
23,461
Common Stock
(indirect: By Trust)
3,609

Footnotes (2)

[F1]By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
[F2]The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT